Véronique Chotteau

Véronique Chotteau’s research focuses on developing new approaches for manufacturing biological prescription drugs, known as biologics. These include monoclonal antibodies, enzymes, viral vectors for gene therapy, and cells for cell therapy, offering life-saving treatments or restoring normal life for patients. Biologics are produced using mammalian, including human cells, or can themselves be the product, requiring complex and costly manufacturing processes due to inherent variability from using living cells as factories. Her research explores process intensification for economic savings and sustainability. For emerging therapies like gene and cell therapy, she develops methods to increase manufacturing capacity, addressing a significant bottleneck for commercialization and the issue of exorbitant costs. Her work includes continuous processing, mathematical modeling, smart monitoring, novel technical solutions or equipment, and often involves industry collaboration.